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Abstract
Coronary artery disease is a leading cause of morbidity and mortality in developed
countries. According to a Center for Disease Control report, one out of four deaths is
attributed to coronary artery disease. It costs the United States human lives, produc‐
tivity, and more than 100 billion dollars each year. Due to increased incidence in both
men and women and all ethnicities, risk stratification of patients at risk for developing
myocardial infarction and death is of paramount importance. Various tests are
available for diagnosis and prognosis in coronary heart disease such as exercise
treadmill testing, coronary calcium scoring, dobutamine stress echocardiography,
exercise, dipyridamole, adenosine or dobutamine stress nuclear myocardial perfusion
imaging (MPI), and dobutamine or adenosine stress cardiac magnetic resonance
imaging. Since 2008 a new vasodilator, regadenoson (REG), has become available and
is now widely used for nuclear perfusion imaging. Pharmacologic stress testing
challenges the coronary flow reserve to evaluate the hyperemic capacity of the heart,
which can be impaired in significant epicardial stenosis or microvascular dysfunction.
In the presence of either of these conditions, ischemia induced by hyperemia manifests
as wall motion abnormalities on echocardiography or as perfusion defects in nuclear
perfusion imaging.
REG is a selective adenosine A2A receptor agonist, and due to its targeted coronary
vasodilator properties and bolus administration of a standard dose in all patients, it
has rapidly gained popularity as the preferred MPI stress agent. In this chapter we
will review the basis of pharmacologic vasodilator stress imaging starting with a brief
discussion of the various adenosine receptors and their function, the structure and
mechanism of action of REG, and its development and approval. It will be compared
with other myocardial perfusion pharmacologic stress agents like adenosine and
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dipyridamole in terms of safety, efficacy, and side effect profile. We will also address
the utility of REG in special situations like renal disease, chronic obstructive pulmo‐
nary disease, heart transplant, left bundle branch block, and paced rhythms. The
prognostic value of REG MPI in the general population, its effectiveness with and
without exercise, and the emerging applications of REG in other modalities of imaging
such as positron emission tomography and stress echocardiography will be discussed.
Keywords: Regadenoson, single photon emission computed tomography, positron
emission tomography, stress echocardiography, fractional flow reserve, coronary
artery disease
1. Introduction
Cardiovascular disease remains a leading cause of death in the United States. According to a
2009 report by the Center for Disease Control, one out of four deaths is attributable to coronary
artery disease (CAD).[1] The increased morbidity and mortality due to CAD poses a huge
economic burden. In 2010, CAD alone accounted for over 100 billion dollars in combined direct
and indirect (i.e., loss of productivity) costs. This is projected to more than double by 2030.[2]
Hence, diagnosing and risk stratifying CAD in its early stages is vital.
Many invasive and noninvasive tests are available to identify patients at high risk of devel‐
oping CAD. Functional tests include exercise stress testing, exercise or dobutamine stress
echocardiography, nuclear myocardial perfusion imaging (MPI) using stress agents such as
dipyridamole, adenosine, dobutamine or regadenoson (REG), and vasodilator stress magnetic
resonance imaging. Coronary computed tomography angiography (CCTA) and the traditional
gold standard, coronary angiography, serve as the two well-established anatomic modalities
used for CAD detection. This chapter will focus on REG, the newest of the pharmacologic stress
agents, and its applications in myocardial perfusion imaging. It will conclude with a brief
overview of some novel applications of REG in cardiology.
2. REG: development, pharmacology, and hemodynamic effects
2.1. Adenosine receptors
Adenosine receptors are located in the myocardium as well as in smooth muscle cells of the
coronary arterioles and the bronchial tree. Various subtypes of adenosine receptors exist
including A1 receptors found in the atrioventricular node, A2A receptors present in coronary
arteriolar smooth muscle, and A2B and A3 receptors located in bronchial smooth muscle. The
different locations and functions of these receptors have been pivotal in the development of
newer pharmacologic stress agents (Figure 1). Adenosine directly and dipyridamole indirectly
act on adenosine 2A (A2A) G-protein-coupled receptors found on the cell membrane of coronary
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arteriolar smooth muscle cells. However, both are nonselective and also activate the other
adenosine receptor subtypes causing frequent clinically important side effects (e.g., atrioven‐
tricular block due to A1 activation and bronchoconstriction due to A2B and A3 receptor
activation) as well as other less serious but often unpleasant side effects. In contrast, REG exerts
its effect selectively on A2A receptors achieving the coronary dilatation necessary to perform
MPI studies while keeping side effects to a minimum.
Note: Springer and J Nucl Cardiol, 17, 2010, 494-497, The emerging role of the selective A2A agonist in pharmacologic
stress testing, Gemignani AS, Abbot BG, Figure 1. With kind permission from Springer Science and Business Media
Figure 1. Types of adenosine receptors, their functions, and activation/inhibition by various pharmacologic agents.
2.2. Development and approval of of REG
Cardiac stress testing is able to identify as well as risk stratify individuals who are at risk for
CAD. Vasodilator stress testing challenges the coronary flow reserve in order to evaluate the
hyperemic capacity of the heart, which can be impaired in significant epicardial stenosis or
microvascular disease and lead to transient ischemia. Ischemic changes manifest either as
perfusion or wall motion abnormalities depending on the imaging modality used. The
currently available pharmacologic stress agents with primarily vasodilator function are
dipyridamole, adenosine, and REG. While dobutamine also vasodilates, it mainly stresses the
heart via its positive inotropic and chronotropic effects.
An ideal cardiac stress agent should cause short-lived but maximal coronary vasodilatation.
Both of these can be achieved if the stress agent has low affinity for its receptor and the target
tissue has many adenosine receptors. The coronary arterial tree has an abundance of A2A
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receptors of which only a fraction needs to be activated to elicit the desired coronary vasodi‐
lation and produce maximal coronary hyperemia. Given the nonspecific nature of adenosine
receptor stimulation by adenosine and dipyridamole leading to undesired side effects, the
need existed for the development of an A2A-selective agent largely devoid of significant side
effects such as bronchospasm and atrioventricular conduction block. REG (code name CVT
3146) was identified as an agent with A2A selectivity yet with a low affinity for A2A receptors,
meaning it dissociates quickly after eliciting maximal coronary vasodilation, thus causing
adequate coronary hyperemia for a short period of time. REG underwent preclinical and
subsequently randomized clinical studies showing non-inferiority compared to the commonly
used vasodilator adenosine. This led to its approval by the Food and Drug Administration in
2008. It is marketed by Astellas Pharma US Inc. under the trade name Lexiscan® in the United
States as a cardiac stress agent for MPI studies in patients who are unable to exercise. Following
REG administration, coronary hyperemia occurs for approximately 2–5 min, which is adequate
for radionuclide uptake and makes it possible to perform stress testing using a single bolus
injection.[3]
2.3. Pharmacology and pharmacokinetics of REG
REG is a 2-[N-1-(4-N-methylcarboxamidopyrazolyl)] adenosine derivative. It is prepared by
condensing ethoxycarbonylmalondialdehyde with 2-hydrazinoadenosine in a 1:1 mixture of
ethanoic acid and methanol. The resulting ester is then converted directly by aminolysis with
methylamine to the amide REG (Figure 2). Alternatively, REG can be prepared from 2-chloro
or 2-iodo adenosine derivatives. The amide links at the 4-position of the N-pyrazolyl, which
has both lipophilic and hydrophilic substituents lending the drug greater affinity for the
adenosine 2A receptor than the other adenosine receptor subtypes.
Figure 2. The molecular structure of REG (CVT-3146; (1-[9-[(4S, 2R, 3R, 5R)-3,4-dihydroxy-5-(hydroxymethyl)oxo‐
lan-2yl]-6aminopurin-2-yl]pyrazol-4-yl)-N-methylcarboxamide).
It is usually given as a single 400-μg (5 mL) intravenous bolus after which it immediately
distributes throughout the body. No weight-based dose adjustment is necessary. REG then
undergoes three phases of elimination. The first is the phase of maximal coronary hyperemia
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lasting 2–4 min.[4] The second phase lasts 15–30 min with profound effect on heart rate and
blood pressure, and the third phase, which lasts for 33–108 min, is clinically nonsignificant.[5]
Much about REG’s metabolism remains unknown; however, its excretion is both renal and
hepatic. The kidneys remove approximately 60% via tubular secretion, while the liver excretes
around 40% of the drug unmetabolized into the bile.
2.4. Hemodynamic effects of REG
As a coronary vasodilator REG is shown to cause tachycardia and changes in blood pressure
(both increase and decrease).Trochu et al.[6] showed in animal studies that while adenosine
increased left ventricular (LV) systolic pressure, REG did not to any significant degree, and
that LV contractility measured by dP/dT increased by 39±7% with REG and 29±7% with
adenosine. The ADVANCE MPI studies[7] have shown that the decrease in systolic and
diastolic blood pressures (BP) was similar between REG and adenosine (systolic BP drop 14±13
mmHg vs. 13±14 mmHg, P = ns; diastolic BP drop 10±8 mmHg vs. 10±8 mmHg, P = ns). Both
drugs increase the heart rate; however, REG more significantly than adenosine (25±11bpm vs.
20±10bpm, P < 0.001).
The increase in heart rate with REG is mainly due to direct sympathetic excitation and less so
from a baroreceptor reflex induced tachycardia. Dhalla et al.[8] has also suggested that an
A2A receptor mediated sinus tachycardia can occur with REG. A blunted heart rate acceleration
with both REG and adenosine has also been observed in studies with diabetic patients and is
felt to be related to sympathetic denervation.[9]
2.5. Side effect profile of REG
Like other vasodilators, REG is associated with many minor and a few major (albeit to a lesser
extent than older vasodilators) side effects of which clinicians need to be aware.[10] Transient
side effects included nausea (6%), abdominal pain (5%), headache (26%), and chest tightness
(13%). In the randomized studies evaluating REG prior to its FDA approval, atrioventricular
(AV) block incidence was <1% with no instances of advanced AV block or asystole in the
ADVANCE MPI 3 studies. However, post marketing surveillance has highlighted rare major
adverse reactions related to REG such as acute myocardial infarction,[11, 12] atrioventricular
block, and asystole.[13] Thus, REG, despite its A2A selectivity, should not be used in patients
with greater than the first-degree AV block unless they have a backup pacemaker. Further‐
more, cases of syncope[14] and seizures[15] have also been reported following REG adminis‐
tration. Although aminophylline is used for reversal of many REG-induced side effects, it
should not be used in the setting of seizures following REG injection as it lowers the seizure
threshold. Instead, standard antiseizure therapy with benzodiazepines and agents such as
phenytoin should be used.
2.6. Effect of caffeine on REG and clinical implications
Caffeine is an A2A receptor antagonist (Figure 1). Hence, it has the potential to attenuate the
hyperemic response, which occurs after vasodilator administration. This is a well-known
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problem with adenosine and dipyridamole, both of which require abstinence from caffeinated
products for at least 24 h prior to stress testing. However, the REG package insert specifies
withholding caffeinated products for only 12 h prior to testing. Preclinical animal studies
suggested that caffeine attenuated the duration of REG-induced coronary hyperemia in dogs.
[16] Subsequent human studies evaluating myocardial blood flow in 41 healthy volunteers
using REG with PET imaging showed that moderate caffeine consumption may not interfere
with REG-induced coronary hyperemia.[17] Thus, conflicting evidence existed regarding the
effect of caffeine on REG stress testing until a multicenter randomized trial on this subject was
performed in 2014.
Tejani et al.[18] studied the effects of caffeine on the diagnostic accuracy of REG single proton
emissions computed tomography (SPECT) MPI in 207 subjects with documented coronary
artery disease on an initial rest-REG SPECT MPI sequence. A third set of SPECT images was
acquired in all patients following randomization to two different caffeine doses (200 and 400
mg) or placebo. Previously noted reversible defects were attenuated in patients who consumed
both doses of caffeine at least 90 min prior to REG administration, thus diminishing the
diagnostic accuracy of the study. There was no difference in adverse effects between the three
groups.[18] Current American Society of Nuclear Cardiology (ASNC) guidelines recommend
that patients refrain from caffeine consumption for at least 12 h before REG stress testing.
Variable Regadenoson Adenosine Dipyridamole
Brand name Lexiscan® Adenocard®/Adenoscan® Persantine®
Indication Pharmacologic stress agentin MPI.
Treatment of paroxysmal
supraventricular tachycardia,
pharmacologic stress agent in
MPI
Oral—antithrombotic along
with warfarin/aspirin.
Intravenous—
pharmacologic stress agent
in MPI
Mechanism of action
Increases coronary flow
reserve (CFR) via selective
A2A adenosine receptor
agonism
Nonselective adenosine agonist
on A1, A2A, A2B, and A3
receptors. Increases coronary
flow reserve (CFR) via
A2Areceptor activation.
Increases availability of
adenosine by inhibiting
adenosine deaminase,
which prevents adenosine’s
breakdown
Potency 10 times more potent thanadenosine Less potent Less potent
Distribution in body 11.5 L Unknown 2–3 L
Metabolism Unknown
In blood and tissue,
metabolized by adenosine
deaminase into inosine and
then adenosine
monophosphate and
hypoxanthine
Hepatic
Time to peak 1–4 min 30 s 2–2.5 h
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Variable Regadenoson Adenosine Dipyridamole
Half-life
Triphasic
First phase = 2–4 min
Second phase = 15–30 min
Third phase = 33–108 min
<10 s 30–45 min
Administration Bolus Infusion Infusion
Dose 400 μg 140 μg/kg/min 0.14 mg/kg/min
Duration of infusion 10-20 s bolus 6 min continuous infusion 4 min continuous infusion
Excretion
57% of drug excreted
unchanged in urine via
tubular secretion
Cellular uptake
Conjugated by glucuronide
and unchanged drug
excreted in feces
Safety in pregnancy Risk cannot be ruled out(Category C)
Risk cannot be ruled out
(Category C)
No evidence of human risk
in controlled studies
(Category B)
Common side effects
Headache 26% , flushing
16%, dyspnea 28%,
hypotension 2%
Headache 21%,
flushing 35%,
dyspnea 19%, hypotension 3%
Headache 12%, flushing
3.4%, dyspnea 2.6%,
hypotension 5%
IV tubing Not needed: only Hep-lock Needed Needed
Protocol completion time
with radiotracer Less than 1 min 4–6 min 6–8 min
Table 1. Comparison of the three commonly used vasodilator agents
Compared with the other two agents, REG is more potent, causes more selective coronary
vasodilatation, can be injected in a single bolus without weight-based adjustments, and
produces SPECT images comparable to adenosine and dipyridamole.
3. REG SPECT MPI in detection of coronary artery disease
3.1. Comparison to adenosine
In a multicenter phase 2 study, REG was tested in 36 patients undergoing SPECT MPI at bolus
doses of 400 and 500 μg. Patients with heart transplantation, left bundle branch block,
ventricular pacemaker, and low ejection fraction (14 patients) were excluded. This study
showed a higher rate of detecting reversible perfusion defects with the lower dose of REG (89%
for 400 μg) than with the higher dose (76% for 500 μg).[19] Subsequently, two phase 3 double-
blinded, randomized, multicenter trials (ADVANCE-MPI 1 and ADVANCE-MPI 2) demon‐
strated non-inferiority of REG SPECT MPI to adenosine SPECT MPI. The ADVANCE-MPI 2
trial included 54 sites and 784 patients undergoing clinically indicated adenosine MPI who
were blindly randomized 4 weeks later to a second MPI study with REG (n = 495) or adenosine
(n = 260) in a 2:1 ratio. Study images were reported in a blinded fashion by three nuclear
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cardiology experts unaware of any patient data. The primary aim of the study was to show
the strength of agreement between sequential adenosine and REG images, and the non-
inferiority of the adenosine-REG sequence to the adenosine-adenosine sequence for consis‐
tently detecting reversible perfusion defects. The investigators demonstrated that the overall
agreement was not statistically different between sequential adenosine–adenosine images
(0.64 ± 0.04) compared to adenosine–REG images (0.63 ± 0.03). Furthermore, there was no
significant difference in image quality between the two stress agents, and the patient tolera‐
bility questionnaire favored REG in this study. In a subsequent quantitative analysis of the
ADVANCE-MPI 2 study, investigators showed that the total perfusion defect size, ischemic
perfusion defect size, ejection fraction, and LV volume estimation was similar between REG
and adenosine.[20] Thus, cumulative evidence collected from over 2000 patients in these
pivotal phase 3 trials demonstrated the non-inferiority of REG to adenosine in SPECT MPI, [7]
as well as the effects of age, gender, obesity, and diabetes on the efficacy and safety of REG[21]
leading to its approval for clinical use.
3.2. REG in special populations
3.2.1. Renal disease
The predominantly renal excretion of REG (60% of the drug) raises concern for its safety in
chronic kidney disease and end stage renal disease patients, including those on dialysis. To
date, two major studies and one prognostic study have shown that REG is not associated with
any major adverse events in this group.
Ananthasubramaniam et al.[22] conducted a randomized, double-blinded, placebo-controlled
multicenter trial to evaluate the safety and tolerability of REG in 432 patients with stage 3
(glomerular filtration rate (GFR) 30–59 mL/min/1.73 m2) and 72 patients with stage 4 (GFR 15–
29 mL/min/1.73 m2) chronic kidney disease. There were no major adverse events within 24 h
of REG injection in the intervention group. Minor adverse effects like headache, dyspnea, chest
discomfort, nausea, flushing, and dizziness were more common in the REG group than in the
placebo group.
Doukky et al.[23] studied 146 ESRD patients undergoing REG stress testing, which included
131 patients on hemodialysis, 12 patients on peritoneal dialysis, and two not on any dialysis.
These were compared with 97 control patients with GFR ≥30 mL/min. The primary end point
of the study was patient reported side effects within 24 h following REG administration. There
were no statistically significant differences in adverse effects between the groups. Interestingly,
end stage renal disease patients tolerated REG stress better than the control group and
expressed their willingness to take the test again (117/131 (80%) vs. 63/97 (65%), P = 0.001).[23]
3.2.2. Asthma and COPD
Adenosine 2B and 3 receptors are located in bronchial smooth muscle cells which, when
activated, can lead to bronchoconstriction (Figure 1). Although REG is a selective A2A receptor
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agonist, there is a concern related to its use in patients with asthma and chronic obstructive
pulmonary disease (COPD).
More than six studies have been performed to evaluate the safety of REG in this population
specifically looking at respiratory symptoms, spirometry parameters, hemodynamic response,
and major adverse events. The combined population of these five prospective studies and one
retrospective study comprised 686 COPD patients and 695 asthmatics.[24] Respiratory
parameters like FEV1, FVC, FEV1/FVC ratio, and patient-reported symptoms were monitored
in most of these studies. All showed that REG is safe in COPD and asthmatics. Dyspnea was
reported more frequently in COPD and asthmatics, but no significant decline in spirometry
measurements occurred among these patients in two double-blinded studies.[25, 26] Of
particular note, Kwon et al.[27] demonstrated that patients who underwent low-level exercise
in conjunction with REG stress reported fewer respiratory symptoms than those who did not
exercise following REG administration.
3.2.3. Pacemaker and left bundle branch block
In patients with left bundle branch block (LBBB), pacemaker, or intrinsic conduction disease,
the increased heart rate caused by either exercise, or dobutamine can lead to false-positive
septal perfusion defects. This is due to a tachycardia-induced decrease in diastolic perfusion
in an already asynchronously activated septum. Multiple studies have compared adenosine
and exercise stress tests in these patients. Caner et al.[28–30] showed that dobutamine stress
testing is associated with higher false positives in LBBB patients, and similar results were
observed in pacemaker patients as well.
The ability of REG to identify perfusion defects in this population was studied by Thomas et
al.[31] In their sub-analysis of the ADVANCE MPI 1 and 2 trials, where all 2015 subjects
underwent SPECT MPI with adenosine followed by SPECT MPI with either REG or adenosine,
64 patients with LBBB and 93 with pacemakers were identified. Hemodynamic changes,
visually assessed summed difference scores (SDS), and quantitative perfusion defects in the
LAD territory and septum were compared between REG MPI and adenosine MPI. The study
showed that although REG led to a significant increase in heart rate compared with adenosine,
it did not cause or exaggerate perfusion defects in the LAD or septal territories either by SDS
or quantitative assessment.[31]
3.2.4. Orthotopic heart transplant patients
Orthotopic heart transplant (OHT) patients have a higher incidence of AV block due to
denervation supersensitivity. Hence, OHT patients who undergo MPI studies are at increased
risk for developing high-grade AV block. Few studies have evaluated the role of MPI in
diagnosing cardiac allograft vasculopathy in these patients.
In a retrospective analysis, Al-Mallah et al.[32] identified 102 OHT patients who underwent
adenosine MPI and compared them with 204 control patients for heart rate, blood pressure
changes, and occurrence of AV block. A threefold increase in the incidence of high-grade AV
block (Mobitz type II and third degree) was seen in OHT patients vs. controls. Symptomatic
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bradyarrhythmias occurred in 2% of OHT patients leading to premature termination of the
adenosine infusion.
OHT patients were excluded from the early trials of REG, which led to its approval, and thus
the safety of REG in this population was initially unknown. The effects of REG in these patients
are particularly relevant, however, given its relative A2A selectivity and the decreased incidence
of AV block observed with REG in other populations. Cavalcante et al.[33] identified 40 OHT
patients who underwent REG MPI. These results were compared with prior adenosine MPI
results in the same patients. There were five episodes of second-degree AV block (Mobitz type
II) and three episodes of sinus pause in adenosine MPI compared with only one episode of
sinus pause in REG MPI. No major adverse effects such as congestive heart failure or death
were reported following REG administration. To reverse REG’s side effects, aminophylline
was given to four patients (two for severe headache and two for chest pressure). However,
REG was largely well tolerated by the OHT patients with no difference in overall adverse effect
profile between the two test drugs.
4. REG in positron emission tomography stress myocardial perfusion
imaging
Although REG was approved in April 2008 by the U.S. Food and Drug Administration for use
in single photon emission computed tomography (SPECT) radionuclide myocardial perfusion
imaging (MPI) as a pharmacologic stressor in patients unable to perform exercise stress testing,
it has not yet been formally approved for use in positron emission tomography (PET) MPI.
Nonetheless, it is increasingly being used in PET MPI in addition to the more established
vasodilators, adenosine and dipyridamole. Over the past several years, PET MPI has become
more accepted into the mainstream for the diagnosis and management of coronary artery
disease (CAD).[34] Furthermore, a recent consensus statement by the American Society of
Nuclear Cardiology recommended PET MPI over SPECT MPI as the preferred initial phar‐
macologic MPI modality if available.[35] The following is a discussion of the current evidence
for REG as a pharmacologic stressor in PET MPI.
4.1. Current guidelines
The 2003 ACC/AHA/ASNC Guidelines for Clinical Use of Radionuclide Imaging recommend
adenosine or dipyridamole myocardial perfusion PET for diagnosis in patients with an
intermediate likelihood of CAD and/or for risk stratification in patients with an intermediate
or high likelihood of CAD.[36] The only class I recommendation is in “patients in whom an
appropriately indicated myocardial perfusion SPECT study has been found to be equivocal
for diagnostic or risk stratification purposes” (Level of Evidence B). Class IIa recommendations
for vasodilator PET MPI are identification of “the extent, severity, and location of ischemia as
the initial diagnostic test in patients who are unable to exercise” and in “patients who are able
to exercise but have LBBB or an electronically-paced rhythm” (both Level of Evidence B). REG
Coronary Artery Disease - Assessment, Surgery, Prevention12
is listed as an additional vasodilator in the 2009 American Society of Nuclear Cardiology
Guidelines.[37]
4.2. PET vs. SPECT myocardial perfusion imaging: advantages and disadvantages
Cardiac PET imaging always includes concomitant CT acquisition for attenuation correction
whereas this is still optional with SPECT. Effective radiation dose is lower with PET despite
high positron emission energy due to very short half-life of rubidium-82 (Rb-82), the most
commonly used PET radiotracer. Ejection fraction (EF) reserve (stress EF – rest EF) is more
accurate with PET than SPECT because PET calculates the EF at peak stress rather than post
stress as with SPECT. Coronary blood flow/flow reserve is possible with PET as myocardial
uptake of Rb-82 bears a more linear relationship to coronary flow rates whereas the uptake of
SPECT tracers plateaus at low flows. This allows for better characterization and localization
of CAD. The superior image quality of PET is related to its high spatial resolution, reduced
scatter, and the high positron emission energy of Rb-82 (1.52 MeV).
Advantages Disadvantages
Higher spatial resolution (2–4 mm vs. 6–8 mm) [38-40] Incompatible with exercise (t 1/2 of Rb-82 only 75 s)
Better count efficiency (more counts in less time) [38-40] Insurance coverage not universal
Superior soft tissue attenuation correction [38, 39] Less availability
Less liver/bowel uptake (less scatter) [40] Motion artifact affects entire image (360° acquisition)
Shorter scan time (5 vs. 16 min) [40] Claustrophobia (longer tunnel)
Less radiation (3.7 vs. 10–22 mSv) [40, 41]
More accurate estimation of EF reserve [42]
Ability to assess coronary blood flow/coronary flow
reserve [34]
Superior diagnostic sensitivity, specificity, and accuracy
[40]
Superior image quality [40]
Increased confidence in interpretation [40]
Table 2. Advantages and disadvantages of Rb-82 PET MPI vs. SPECT MPI
Sensitivity (PET/SPECT) Specificity (PET/SPECT) Accuracy (PET/SPECT)
>70% stenosis 87%/82% (ns) 93%/73% (P = 0.02) 89%/79% (P = 0.03)
>50% stenosis 86%/81% (ns) 100%/66% (P = 0.00008) 87%/71% (P = 0.003)
Table 3. Overall sensitivity, specificity, and diagnostic accuracy of PET vs. SPECT MPI for both moderate and severe
degrees of coronary stenosis
Comparison of 112 SPECT MPI (using adenosine and Tc-99m) and 112 PET MPI (using
dipyridamole and Rb-82) in populations matched for gender, BMI, and presence/extent of
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CAD.[40] “Specificity” includes low-likelihood patients who did not undergo angiography in
addition to angiographically normal patients. “ns” = not statistically significant.
4.3. Advantages of REG in PET MPI
The increase in coronary blood flow is over 100 times greater with REG than adenosine. Rapid
onset of hyperemia (less than 1 min after injection) with peak hyperemia occurring about 2.3
min following injection[3] along with weight-independent standardized dosing make REG
well suited for use with short-acting PET radiotracers such as Rb-82 (t1/2 = 75 s). Rapid testing
is thereby facilitated with the stress portion lasting less than 1 min. When using REG stress
together with PET imaging, the entire test duration is only 16–18 min. Figure 3 is a flow diagram
of the REG PET MPI protocol used by Hsiao et al.[43]
Reproduced with permission. Hsiao E, Ali B, Blankstein R, et al. Detection of obstructive coronary artery disease using
regadenoson stress and 82Rb PET/CT myocardial perfusion imaging. J Nucl Med 2013;54:1748–54.
Figure 3. Rest-stress regadenoson [82]Rb PET/CT protocol. After scout CT acquisition (120 kVp, 10 mA), CT transmis‐
sion scan (CTAC) (140 kVp, 10 mA, pitch of 1.35) was acquired. Patients received 1,480-2,220 MBq of [82]Rb intrave‐
nously at rest, and emission images were acquired in 2-dimensional list mode. After rest imaging, patients remained in
scanner gantry for stress imaging. Stress was induced with 0.4 mcg of regadenoson given intravenously over 10 s fol‐
lowed by 10-mL flush with normal saline. Immediately after saline flush, second dose of 1,480-2,220 MBq of [82]Rb
was administered intravenously approximately 30 s after regadenoson injection and emission images were acquired as
previously described. Ordered-subsets expectation maximization (30 iterations and 2 subsets) and 3-dimensional PET
filtering (Butterworth filter, cutoff frequency of 10, order of 5) were used for reconstruction of images.[43]
4.4. Coronary flow reserve using PET
The ability to quantitatively assess coronary blood flow (CBF) and coronary flow reserve (CFR)
on angiography was discovered by Gould in animal experiments during the mid 1970s.[44]
Because PET image acquisition occurs during peak stress, calculation of CFR (peak flow ÷ rest
flow) is one of the unique features of PET as opposed to other noninvasive imaging modalities.
A “normal range” has proved difficult to define given the disparity between coronary flows
in asymptomatic patients. Based on pooled data from nearly 15,000 patients in 252 studies
using three different PET isotopes, CFR in patients without CAD is 3.55 ± 1.36. In patients with
established coronary disease, this drops to 2.02 ± 0.70.[45] Table 4 displays the range of values
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for absolute coronary flow and CFR in the presence of CAD risk factors and other forms of
cardiac disease. One of the larger studies in the literature, however, identified a CFR of 1.74
as the cutoff for “definite ischemia” below which patients manifest anginal symptoms and/or
ischemic ECG changes during vasodilator stress testing matched by a significant perfusion
defect on PET imaging.[46]
Reproduced with permission. Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of
coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography
imaging in revascularization decision-making. J Am CollCardiol2013;62:1639–53.
Table 4. Graded Absolute Flow and Coronary Flow Reserve Across Spectrum of Disease : n=14,962[45]
Not until recently was the clinical utility of PET-derived CFR fully appreciated. A study of 205
patients (using REG in half of these) demonstrated that with a negative predictive value of
97%, normal global CFR virtually assures the absence of high-risk CAD, despite any coexistent
abnormal perfusion.[47] However, as a reduced CFR can occur in three different conditions
(diffuse non-obstructive atherosclerosis, significant epicardial coronary stenosis, and micro‐
vascular disease), it can be somewhat helpful but is not specific for selecting patients likely to
have high-risk CAD on angiography. A very recent study of PET-derived CFR further
illustrated that low CFR can be seen in patients with systolic cardiomyopathy (EF ≤ 45%) of
both ischemic and non-ischemic etiologies.[48] Murthy et al.[49] studied 2783 patients with
known or suspected CAD referred for rest/stress PET MPI and then followed over a median
of 1.4 years. Those in the lowest CFR tertile (<1.5) had a 16-fold increase in risk of cardiac death
versus those in the highest tertile (>2.0). The middle tertile had a 5.7-fold increase in risk
compared to the highest tertile. The addition of CFR to clinical and standard MPI factors led
to the correct re-categorization of 34.9% of patients in the intermediate-risk group. Patients in
this study received one of four different vasodilators (adenosine, dipyridamole, dobutamine,
or REG). As resting CBF was similar between all three tertiles, the reduction in CFR was
primarily driven by lower CBF with stress suggesting impaired coronary vasodilator function
as an etiology. No difference was drawn between the various vasodilators used, however.
Very little has been published on the specific use of REG to assess CFR in Rb-82 PET MPI. Van
Tosh et al.[50] used REG alone to show that CFR corresponded with LV dysfunction (LVD)
during stress and that regional reductions in CFR were more often present in patients with
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LVD than those without, indicating that the phenomenon of coronary steal may be involved
in the genesis of LVD.
4.5. REG PET MPI vs. dipyridamole PET MPI
There exist scant data comparing REG and dipyridamole in PET MPI. A recent study retro‐
spectively assessed CBF and CFR using Rb-82 perfusion PET/CT in 104 matched patients with
normal stress tests, half with dipyridamole and half with REG. No significant difference in
stress CBF and CFR was found between the two vasodilators (Figure 4). Further supporting
REG’s usefulness as a stress agent was the lack of any correlation between stress CBF or CFR
and patient weight or BMI.[51]
Reproduced with permission. Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel FM. Comparison of the myocardial
blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb
myocardial perfusion PET. Eur J Nucl Med Mol Imaging2011;38:1908–16.
Figure 4. Myocardial blood flow (MBF) and myocardial flow reserve (MFR) in subjects undergoing pharmacological
stress with regadenoson versus dipyridamole. a No significant difference in MBF between groups at rest (left, p=0.77)
or during stress (right, p=0.39). b No significant difference in MFR (p=0.31).[51]
A very recent study by Johnson and Gould compared CFR in patients undergoing two
sequential PET MPIs, either both with dipyridamole (n = 50) or with dipyridamole and REG
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(n = 126).[52] In the latter group, various timings between REG administration and activation
of the Rb-82 generator were used. It was demonstrated that using the timing recommended in
the REG package insert (10–20 s between REG injection and radioisotope injection), the stress
CBF and CFR with REG were only 80% of the hyperemia attained with dipyridamole. By
increasing this interval to 55 ms, this percentage was increased to 90%. These findings suggest
that with the current timing recommendation, REG remains inferior to diypirdamole in
detecting stress CBF and CFR.
The shorter duration of peak hyperemia with REG (2.3 min) than dipyridamole has raised
some concern as to whether Rb-82 uptake by the myocardium would be sufficient to register
perfusion defects or changes in cardiac function with the newer vasodilator. Cullom et al.[53]
studied 32 patients, all of whom underwent both REG and dipyridamole PET MPI, and
compared summed stress and difference scores, total perfusion deficit, LVEF, LV volumes,
and change in stress-rest function. They determined that REG and dipyridamole yielded
equivalent measures of cardiac perfusion and function.
To date, there are no published investigations of REG vs. adenosine in PET myocardial
perfusion imaging.
4.6. Diagnostic accuracy of REG PET MPI
Studies comparing vasodilator stress SPECT and PET MPI have repeatedly demonstrated
slightly higher sensitivity in PET (90%) than SPECT (80–84%) but far greater specificity in PET
(89%) than SPECT (53–76%).[34, 38, 39] Table 5 summarizes the results of all published
literature on the diagnostic accuracy of PET through 2007. Most of these studies used Rb-82 as
a tracer and dipyridamole ± handgrip for stress. One included dipyridamole, adenosine, and
dobutamine stress, and one used exercise stress with ammonia-N13 PET imaging.
*Study using PET/CT (in which CT was used for attenuation correction only).
PPV= positive predictive value; NPV= negative predictive value; NR= not reported. (Reprinted with permission of (28).)
Reproduced with permission. Di Carli MF, Dorbala S, Meserve J, El Fakhri G, Sitek A, Moore SC. Clinical myocardial
perfusion PET/CT. J Nucl Med2007;48:783–93.
Table 5. Summary of Published Literature with Regard to Diagnostic Accuracy of PET[34]
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Hsiao et al.[43] performed the first and so far only published study to evaluate the diagnostic
accuracy of REG in PET MPI. In a relatively small cohort of 134 patients in 98 of whom
angiographic data were also available, its accuracy was found to be similar to that of PET MPI
using other vasodilators. Sensitivity for obstructive CAD was 92%, and overall specificity was
77% (53% in patients with high likelihood of CAD but no angiographic evidence of obstructive
disease and 93% in low likelihood patients who did not go on to angiography [normalcy rate]).
The area under the receiver–operator curve was 0.847, comparable to the high accuracy rates
of PET in previous studies.
The high sensitivity of PET MPI for detection of obstructive CAD can be further increased by
PET’s ability to quantify blood flow/flow reserve and to calculate LVEF reserve using peak-
stress LVEF.
4.7. Prognostic value of REG PET MPI
It has been shown that the prognostic value of REG is comparable to that of adenosine in
patients with normal SPECT myocardial perfusion tests.[54] There are no published data on
the prognostic value of REG in PET MPI, nor of REG MPI in patients with abnormal results
using either PET or SPECT. Recent studies, however, offer insight as to the prognostic value
of LVEF reserve in vasodilator stress PET.
Dorbala et al.[42] established that LVEF reserve (stress LVEF – rest LVEF) is independently
predictive of the extent of at-risk myocardium on Rb-82 PET MPI and the extent of CAD on
invasive angiography. Based on these results, LVEF reserve >5% essentially rules out severe
3-vessel or left main disease with a negative predictive value of 97%. In 985 patients with gated
vasodilator stress Rb-82 PET MPI, nearly half of whom were at intermediate risk for CAD
consistent with contemporary practice, the same group of investigators showed that during a
mean follow-up period of 1.7 years, the frequency of cardiac events and all-cause death was
higher in patients with LVEF reserve <0 than in those with LVEF which either remained the
same or augmented with stress.[55] The prognostic value of LVEF reserve was found to be
independent of, and incremental to, clinical variables and rest LVEF. These studies, however,
included only patients who had received either dipyridamole or adenosine.
Hsiao’s was the first group to investigate LVEF reserve using REG PET MPI, albeit in a much
smaller cohort of 115 patients. Here, LVEF reserve with REG was inversely related to the
severity of reversible perfusion defect (summed difference score) as well as jeopardized
myocardium on coronary angiography (Duke Jeopardy Score)[43] (Figures 5 and 6). This
suggests that REG may be as useful as dipyridamole or adenosine in determining LVEF
reserve; however, further studies are still needed to evaluate its prognostic value.
4.8. Future directions for REG PET MPI
The IDEALPET (Integrated Dual Exercise and Lexiscan PET) study is currently underway and
will compare Lexiscan© alone with Lexiscan© plus exercise (“Lexercise”) with regards to
safety, tolerability, myocardial perfusion image quality, and assessment of relative and
absolute myocardial perfusion.[56]
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Reproduced with permission. Hsiao E, Ali B, Blankstein R, et al. Detection of obstructive coronary artery disease using
regadenoson stress and 82Rb PET/CT myocardial perfusion imaging. J Nucl Med2013;54:1748–54.
Figure 5. Regadenoson LVEF reserve as function of relative MPI results. Mod=moderate.[43]
Reproduced with permission. Hsiao E, Ali B, Blankstein R, et al. Detection of obstructive coronary artery disease using
regadenoson stress and 82Rb PET/CT myocardial perfusion imaging. J Nucl Med2013;54:1748–54.
Figure 6. Regadenoson LVEF reserve as function of Duke Jeopardy Score. LLK= low likelihood.[43]
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As of February 2011 REG was being used in 68% of all pharmacologic stress MPI studies in
the United States.[54] Given its already widespread use and favorable profile as a stress agent
plus the advantages inherent in Rb-82 PET perfusion imaging (superior image quality, shorter
scan time, lower radiation dose to patient, quantitation of myocardial blood flow, measure‐
ment of peak LVEF, additional prognostic information), REG PET MPI has the capacity to
become the pharmacologic stress test of choice over the next several years.
5. Novel applications of REG
5.1. Adjunct to exercise MPI
Exercise-based testing has been convincingly shown to provide powerful prognostic data and
remains the preferred mode of stress testing if patients are capable of exercising.[57, 58]
However, about 25% of exercise-based testing may be non-diagnostic due to inability to
achieve target heart rates. Two alternatives for these patients have been evaluated in the past:
either rescheduling for pharmacologic stress or immediately attempting adjunctive vasodila‐
tor stress with agents such as adenosine and dipyridamole.[59, 60] The combination of
simultaneous adjunctive low-level exercise with adenosine or dipyridamole helps both to
lessen side effects and improve image quality.[61, 62] However, trying to add on adenosine or
dipyridamole when exercise testing is submaximal poses major challenges as both are given
as an infusion over a few minutes, need to be adjusted for weight or delivered via pump (as
in the case of adenosine), and thus are not immediately feasible. In these instances, patients
are usually rescheduled for a pharmacologic stress test when exercise testing is submaximal.
With the advent of rapid-acting, weight-independent, single-bolus dosing of REG, its use as
an adjunct to exercise seemed logistically feasible and potentially convenient. Its administra‐
tion could result in quick conversion of an otherwise non-diagnostic nuclear exercise stress
study due to submaximal heart rate to a diagnostic one. Early data support such a practice.
Thomas et al.[63] evaluated the safety of REG during exercise in a double blind study of 60
patients focusing on image quality, patient acceptance, and detection of perfusion defects.
Patients undergoing a clinically indicated adenosine supine MPI were subsequently
randomized in a 2:1 fashion to REG with low-level exercise (RegEx) or placebo with low-
level exercise (PlcEx). This small study showed no significant differences in blood pressure
response between the RegEx and PlcEx groups, although a smaller increase in heart rate was
noted in the RegEx than in the PlcEx group. The image quality was better with REGEx com‐
pared to the adenosine supine MPI images. Patient tolerability was also reported to be better
with RegEx compared to adenosine supine MPI. No significant adverse events, including
high-grade AV block, were reported in the RegEx group.
In a subsequent study, Kwon et al.[27] published their retrospective experience with 1263
patients undergoing REG MPI with either adjunctive low-level treadmill exercise (n = 596)
or as a standard supine REG stress test (n = 667). Among all participants an asymptomatic
drop in systolic blood pressure > 10 mmHg occurred in 51% and > 30 mmHg in 9%. A pres‐
sure drop was observed more often in those randomized to REG plus low-level treadmill ex‐
ercise (56%) than in those undergoing supine REG (47%). In their COPD/asthma patients
Coronary Artery Disease - Assessment, Surgery, Prevention20
(16%), REG with low-level exercise was well tolerated, and they also reported lower inci‐
dence of nausea, shortness of breath, transient heart block, palpitations, and dizziness over‐
all in those who underwent low-level exercise.
Our own experience comparing REG MPI (n = 887) to REGWALK MPI (n = 485) (REG with
adjunctive low-level exercise) was published as a retrospective series. We showed that REG‐
WALK studies demonstrated higher stress heart rate response, higher heart rate reserve,
and higher systolic blood pressure with stress. There was less use of aminophylline for re‐
versal of REG side effects in the REGWALK compared to the REG group. No major adverse
events were reported in this series.
No data exist showing improved detection of ischemia/prognosis by combining REG with
exercise. A few randomized studies have assessed the safety and efficacy of REG when used
as an adjunct to maximal exercise when target heart rate is not achieved. Ross et al.[64]
randomized 200 patients undergoing exercise MPI to either adjunctive REG if target heart
rate was not achieved at peak exercise or to the discontinuation of exercise with conversion
to a standard supine REG stress test. They showed that both approaches were well tolerated
without any adverse events. There were no differences in ischemia detection, image quality
or referral to cardiac catheterization in either group. Another small randomized study (n =
140) also showed that augmenting submaximal exercise with REG as needed was safe in pa‐
tients.[65] In an effort to finalize the evaluation of REG’s safety as an adjunct to exercise, a
large randomized trial has just been completed by Astellas.[66] Results of this study will
conclusively address not only the safety of REG with exercise but also the detection of ische‐
mia when compared to REG alone.
5.2. Fractional Flow Reserve (FFR)
The concept of reactive hyperemia is particularly useful in guiding percutaneous coronary
intervention (PCI) when intermediate coronary lesions of unclear hemodynamic significance
are present on invasive angiography.[67, 68] More recently, seminal studies have firmly
established that FFR-guided decision making for coronary lesions of unclear significance is
associated with a favorable outcome with PCI being deferred or performed based on FFR
values.[69] Most catheterization labs use either intracoronary or intravenous adenosine for
assessment of hyperemic response.[70, 71] However recent studies have now shown that REG
may be a viable alternative to adenosine with its weight independent bolus and rapid ach‐
ievement of hyperemia in 33–40 s, thus shortening the entire time needed for FFR assessment.
[72, 73] In a study of 25 patients undergoing catheterization, Nair et al.[72] compared the ability
of IV adenosine and IV REG to induce coronary hyperemia in assessment of coronary stenosis
significance. They found excellent linear correlation for measurement of FFR between the two
agents (r = 0.985, P = 0.001). Furthermore, none of the hemodynamically significant lesions
(FFR <0.8, 52% of patients) identified by adenosine were reclassified by REG. There were no
significant adverse reactions to either drug and REG was overall better tolerated than adeno‐
sine.[72] In a more recent study by Prasad et al.,[74] the authors compared 57 patients (60
lesions) undergoing FFR measurements first with adenosine followed by a 10 min washout
phase and then with REG. They showed high correlation in hyperemic response between the
two drugs (R2 = 0.93) (Figure 7) and substantially shorter time to peak hyperemia with REG
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than adenosine as well as a trend to a better side effect profile with REG. One issue of concern
raised by these authors has been the potential cost of a single vial of REG (around 250 dollars)
compared to a 3-min adenosine infusion (80 dollars). However, such cost differences could be
made up by shorter duration of REG administration, no need for infusion pumps and less
nursing time for set up. A recent randomized study of 100 patients has also shown that REG
is equivalent to central venous infusion of adenosine to induce maximal hyperemia for FFR
determination.[75]
In summary, the data accumulated on REG in FFR suggest that it could very well be the
preferred agent in the catheterization lab given its ease of use and proven efficacy and
comparability to adenosine.
5.3. Stress echocardiography
The detection of CAD using stress echocardiography (SE) is based on the physiologic principle
of stress-induced subendocardial ischemia causing wall motion abnormalities in the territory
subtended by stenosis. Exercise and dobutamine (DSE) are the main methods of SE in North
America,[76] whereas high-dose dipyridamole supplemented with atropine has been the
mainstay pharmacologic stressor in Europe.[76, 77]
It  is  well  known that  wall  motion can be completely  normal  with DSE despite  mild to
moderate stenosis and corresponding abnormalities in hyperemic blood flow.[78] Using a
newer technique of myocardial contrast echocardiography (MCE), contrast imaging during
induced hyperemia allows for the detection of milder degrees of coronary stenosis. Similar
to nuclear perfusion imaging, MCE is able to pick up small perfusion abnormalities, which
occur prior to ischemic changes in wall motion, in keeping with the “ischemic cascade.”
Prior  studies  using  adenosine,  dobutamine,  and  exercise  with  MCE  have  shown  that
myocardial contrast perfusion enables detection of moderate stenosis when added to wall
motion.[79–81]
Given its ease of use, there has been interest in using REG as a vasodilator to induce hypere‐
mic stress during MCE. In a study of 100 patients undergoing quantitative coronary angiog‐
raphy, Porter et al.[82] performed real-time MCE with Definity 3% infusion at baseline and
then at 2-min intervals for up to 6 min after a REG bolus. This study showed that MCE with
REG can detect noncritical coronary stenosis (>50% diameter) with sensitivity, specificity,
and accuracy of 80%, 74%, and 75%, respectively, which was better than wall motion analy‐
sis alone (60%, 70%, and 66%, respectively (P < 0.001 for sensitivity)). Furthermore, the au‐
thors concluded that the sensitivity was highest when imaging was performed 4–6 min after
REG administration.[82] In a recent study performed in 10 dogs with mild to moderate non
flow limiting CAD, Le et al.[83] used REG (5 μg/kg, 10-s bolus) along with MCE and as‐
sessed myocardial blood volume, flow velocity, and total regional myocardial flow before
and after REG administration. REG induced an increase in coronary blood flow for 30 min.
This decreased proportionally to stenosis severity, and perfusion defects were visible for up
to 10 min after REG bolus. They noted that the optimal time for imaging myocardial perfu‐
sion in stress echo with REG was between 3 and 10 min after REG bolus.[83]
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Our group recently reported on 44 patients undergoing diagnostic angiography based on
prior abnormal stress testing who also underwent a novel protocol called REGAT (REG +
atropine) SE to assess feasibility, safety, and diagnostic accuracy of CAD detection. The test‐
ing sequence began with administration of 2 × 1 mg boluses of atropine to induce chronotro‐
Prasad et al.: CCI; 2014;83;365–74 [74]
Reproduced with permission Prasad A, Zareh M, Doherty R, et al. Use of regadenoson for measurement of fractional
flow reserve. Catheter CardiovascInterv2014;83:369–74.
Figure 7. Average of FFR with Adenosine and FFR with Regadenoson[74]
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py followed by a 400-μg bolus of REG, and then echo imaging at peak stress starting 20 s
after the REG bolus. The protocol was found to be safe and well tolerated with no serious
adverse effects. The mean duration of REGAT SE was 18 ± 7 min. Significant CAD (≥70%
stenosis) by angiography was present in 51.1%. Sensitivity, specificity, and positive and neg‐
ative predictive values for REGAT SE were 60.9%, 80.4%, 82.4%, and 67.9%, respectively. By
coronary territories, the sensitivity, specificity, PPV, and NPV were as follows: left anterior
descending artery, 58.8%, 92.9%, 83.3%, and 78.8%; left circumflex artery, 6.7%, 93.3%,
33.3%, and 67.7%; and right coronary artery, 16.7%, 93.9%, 50%, and 75.6%. Over 90% of
subjects reported feeling comfortable, with 83% preferring REGAT as a future stress modali‐
ty. We concluded that although the REGAT protocol was fast, safe, and well-tolerated with
good specificity for CAD detection, its low sensitivity and NPV preclude it from routine use.
Importantly, contrast was not utilized in our study as we were testing the feasibility of a
combination of REG and atropine. Overall evidence indicates that REG in SE may be feasible
and safe and, but larger studies are needed in this area as concern still exits that echocardio‐
graphic imaging may not detect ischemia induced by vasodilator stress.
5.4. Coronary CT Angiography (CCTA) and stress perfusion
It is now well established that CCTA performs with high diagnostic sensitivity and has
excellent negative predictive value for the noninvasive evaluation of CAD[84, 85] However
the specificity and positive predictive value have been shown to be less than desired with
overestimation of stenosis severity in published studies[86, 87]. When compared to fractional
flow reserve or SPECT even apparent high grade stenosis diagnosed on CCTA has not be
consistently associated with ischemia[87]. This has raised some concerns that CCTA as a
noninvasive modality for CAD may lead to higher false positives and downstream testing.
CCTA stenosis detection requires additional physiologic information to correctly identify
physiologic significant lesions. Until recently evidence for ischemia evaluation with CCTA has
been very limited. The concept of combining stress perfusion with CT (CTP) has been tested
and found to be accomplished in many single center studies mainly using adenosine or
adenosine triphosphate. This has raised the possibility that a comprehensive anatomic and
physiologically CAD assessment could be feasible by CCTA+CTP. [88-90]
Most recently a multicenter study sponsored by Astellas was completed and published
evaluating the non-inferiority of REG CTP to REG SPECT. Patients (men > 45 years; women >
50 years) with known or suspected coronary artery disease (n=124) were randomized to 1 of 2
diagnostic sequences: rest/REG SPECT MPI on day 1, then REG/rest CTP on day 2, or REG/
rest CTP on day 1 followed by rest/REG SPECT MPI on day 2. CCTA was also performed
during the same acquisition as the CTP in both groups. Scanning platforms included 64-, 128-,
256-, and 320-slice systems. The primary analysis examined the agreement rate between CTP
and SPECT for detecting or excluding reversible ischemia in 2 myocardial segments as assessed
by independent blinded readers. Across the 110 patients included in the final analysis REG
CTP was non-inferior to SPECT for detecting or excluding reversible ischemia with an
agreement rate of 0.87 (95% confidence interval [CI], 0.77-0.97) and sensitivity and specificity
of 0.90 (95% CI, 0.71-1.00) and 0.84 (95% CI, 0.77-0.91), respectively. The agreement rate for
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detecting or excluding fixed defects by REG CTP and SPECT was 0.86 (95% CI, 0.74e0.98). With
SPECT as the reference standard, the diagnostic accuracies for detecting or excluding ischemia
by REG CTP and CTA alone were 0.85 (95% CI, 0.78-0.91) and 0.69 (95% CI, 0.60-0.77),
respectively. The authors concluded that REG CTP is non-inferior to SPECT. Thus, CT
vasodilator stress perfusion imaging either with REG or adenosine appears to have a prom‐
ising role in providing physiologic information to clarify anatomic stenosis. Further studies
are awaited to establish this modality in clinical practice.
6. Conclusion
We have aimed to provide the reader in this chapter a detailed overview of REG and its current
status in cardiac stress testing and other emerging cardiac applications. The role of REG
remains to be better defined in cardiac MRI and CT.
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